Looks like this company is starting to get its act together....

Looks like this company is starting to get its act together. Should see a significant increase in the stock price as the influx of experts is a definately a positive step forward. Looking at a 25 - 40% increase in the next couple of months. Good luck all.

The committee members are:
• Professor Julia Potter: Professor of Pathology at the Australian National University
and Director of ACT Pathology which is responsible for administering pathology
services in both ACT and regional NSW (Southern Area Health Service). Professor
Potter has science as well as medical qualifications with a PhD in science from the
John Curtin Medical School. In her previous role as the Director of Chemical
Pathology Queensland Health Pathology Service and Director of Chemical Pathology
at the Royal Brisbane Hospital’s Herston Campus she was responsible for upgrading
POC pathology services across Queensland.
• Dr Graham Jones: Head, Chemical Pathology SydPath, St Vincents Hospital,
Darlinghurst. Dr Jones has both medical training and a PhD in science and is a
Fellow of the Australian Association of Clinical Biochemists. He brings experience in
the management of a routine hospital pathology laboratory and the evaluation of the
analytical performance of testing equipment and reagents in both central laboratory
and POC settings.
• Dr Renze Bais: Head of the Express Laboratory, Pacific Laboratory Medicine Services,
Royal North Shore Hospital, Sydney and Associate Senior Lecturer, Department of
Medicine, University of Sydney. Dr Bais has over 20 years experience in major
laboratories in Australia. He graduated from the University of Adelaide and has a PhD in
enzymology. Renze is a member of the Council of the Australasian Association of Clinical
Biochemists and is Chair of the Scientific and Technical Committee. He has been actively
involved in the IFCC for many years, first as a member of the Enzyme Committee, then
the Scientific Division including a term as Secretary and now as Secretary of the
Executive Board.
• Dr Michael Cooper: Dr Cooper is Head of the Endoscopic Surgery Unit at the Royal
Prince Alfred Hospital, Sydney and has international experience in small hole
laparoscopic surgery for gynaecological and other applications. Michael brings to the
committee expertise and advice on POC diagnostic needs from a surgeons
perspective. His association with Ambri is driven by his enthusiasm to increase the
level of diagnostic test information to the operating theatre to enhance the quality and
safety of surgical procedures.
• Mr Russell Richards: Mr Richards is the former General Manager of AGEN Biomedical
Limited the prime operating company of Agenix Limited, an ASX-listed biotechnology
company. He has a strong background in product development, operations, marketing
and corporate management. He also has a practical knowledge of the important issues
faced by laboratory users of biomedical products. Prior to joining AGEN, Mr Richards
was a medical scientist at the Princess Alexandra Hospital. He holds a Bachelor of
Science (Hons) in Biochemistry and Mathematics, and a Master of Science degree in
Biochemistry.
• Dr Andrew St John: Dr St John is a specialist in POC applications and has both a
background in the clinical laboratory and international industry experience in the
development and commercialisation of medical devices. He has a special interest in
promoting evidenced based medicine which is crucial for the introduction of new
technology to derive the maximum clinical benefit.
Dr Bruce Cornell, Ambri’s Chief Scientist chaired the meeting.